© 2020 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
April/May 2020 Survey
Activists want the tech giant to take down similar ads with inaccurate claims about PrEP and HIV prevention.
More than 50 AIDS and LGBT groups demand the tech giant remove “dangerous and misleading” PrEP ads.
The first meta-analysis to examine hep C treatment outcomes in seniors versus non-seniors found that cure rates are comparable.
POZ contributing writer Shawn Decker shares his journey from being a kid with no real treatment options to now.
Researchers compared data on more than 9,000 people with HIV who took either version of tenofovir.
A look at 2009 to 2014 data found that those in care for HIV saw a considerable fall in treatment deferrals.
While we can surely appreciate that some prescription drugs are necessary and life-saving, most are not-- and only cause more problems.
In a recent study, Edurant was better tolerated and less toxic and led to fewer discontinuations.
This finding came from a larger report indicating that U.S. residents are increasingly taking drugs linked to such symptoms.
Those on Tybost-boosted Vitekta are more than twice as likely as those taking Tivicay to switch meds because of adverse health events.
Researchers combed through relevant research and were not able to draw strong conclusions about the effectiveness of antidepressants.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
